Table 5 Univariate sensitivity analyses
| Â | Potential savings (per inhabitant) | ||||||
|---|---|---|---|---|---|---|---|
| Â | Main scenario | Proportion of the population treated for hypertension increased to 9.4% | Proportion of patients with hypertension and CVD* that can take thiazides increased from 0% to 40% | Proportion of persons treated for hypertension that have CVD* increased from 40% to 50% | Proportion of persons treated for hypertension that have CVD* decreased from 40% to 30% | Proportion of persons with uncomplicated hypertension that can use thiazides decreased from 75% to 65% | Proportion of persons with uncomplicated hypertension that can use thiazides increased from 75% to 85% |
Canada | $13.8 million ($0.44) | $94.8 million ($3.03) | $45.6 million ($1.46) | $-7.9 million ($-0.25) | $35.5 million ($1.14) | $-3.6 million ($-0.11) | $31.2 million ($1.00) |
France | $37.4 million ($0.63) | $72.8 million ($1.23) | $51.4 million ($0.87) | $28.0 million ($0.47) | $46.9 million ($0.79) | $29.9 million ($0.50) | $45.0 million ($0.76) |
Germany | $72.2 million ($0.87) | $158.9 million ($1.92) | $106.3 million ($1.28) | $48.9 million ($0.59) | $95.4 million ($1.15) | $53.6 million ($0.65) | $90.8 million ($1.10) |
Norway | $10.7 million ($2.40) | $18.6 million ($4.15) | $14.3 million ($3.19) | $8.3 million ($1.86) | $13.2 million ($2.94) | $8.8 million ($1.96) | $12.7 million ($2.83) |
UK | $119.7 million ($2.01) | $119.7 million ($2.01) | $199.8 million ($3.36) | $65.1 million ($1.09) | $174.3 million ($2.93) | $76.0 million ($1.28) | $163.4 million ($2.75) |
US | $433.6 million ($1.57) | $808.9 million ($2.94) | $873.5 million ($3.17) | $133.6 million ($0.49) | $733.5 million ($2.66) | $193.6 million ($0.70) | $673.5 million ($2.44) |